{"description":"there were no events reported in the five participants enrolled in the treatment arm or in the five participants enrolled in the observation arm of this study.","eventGroups":[{"description":"Bortezomib will be administered as 12 monthly courses of 1.0 mg/m2 on days 1, 4, 8, and 11 and repeated every 28 days, followed by cycles administered every other month in year 2, and then every 3 months in year 3","id":"EG000","otherNumAffected":0,"otherNumAtRisk":5,"seriousNumAffected":0,"seriousNumAtRisk":5,"title":"Treatment Arm"},{"description":"Patients will be observed for progress over the course of three years.","id":"EG001","otherNumAffected":0,"otherNumAtRisk":5,"seriousNumAffected":0,"seriousNumAtRisk":5,"title":"Observation Arm"}],"frequencyThreshold":"0"}